Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Early secretory antigenic target 6 kDa (ESAT-6) is a potent T-cell antigen produced by Mycobacterium tuberculosis and is a key virulence factor secreted via the ESX-1 secretion system (UniProt: P9WNK5). It plays a critical role in the pathogenesis of tuberculosis by facilitating the escape of the bacteria from the phagosome into the cytosol of host macrophages, thereby promoting intracellular survival and spread. Because ESAT-6 is present in virulent M. tuberculosis but absent in the vaccine strain Bacillus Calmette-Guérin (BCG), its antigenic epitopes are highly specific targets for diagnostic assays like Interferon-Gamma Release Assays (IGRAs). In therapeutic development, ESAT-6 epitopes are incorporated into subunit vaccines designed to boost or replace BCG-induced immunity by eliciting a robust Th1-mediated immune response. These epitopes are recognized by both CD4+ and CD8+ T-cells, making them central to modern tuberculosis vaccine strategies and diagnostic differentiation between infected and vaccinated individuals. The protein also interacts with host cell receptors such as Toll-like receptor 2 (TLR2), modulating the host's innate immune response to favor persistent infection. Furthermore, ESAT-6 forms a 1:1 heterodimer with CFP-10, which is essential for its stability and secretion.
Induction of cell-mediated immunity through the presentation of epitopes on MHC molecules to T-lymphocytes, triggering IFN-gamma release and macrophage activation.
4 more in the full profile.
Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Early secretory antigenic target 6 kDa (ESAT-6) (ESAT-6).